Back to today’s briefing

Story perspectives

Camzyos Trial Fails, Stock Dips; Rivals Gain Ground

4/15/2025

34 6

Summary

Story summary

Bristol Myers Squibb's Camzyos stumbled in a critical trial for non-obstructive hypertrophic cardiomyopathy, falling short of key goals after 48 weeks. This disappointment led to a 2.7% dip in its stock, while rival Cytokinetics may find new opportunities for its drug aficamten. Analysts emphasize the unique challenges posed by different forms of HCM.

1 of 1

Story summary

Bristol Myers Squibb's Camzyos stumbled in a critical trial for non-obstructive hypertrophic cardiomyopathy, falling short of key goals after 48 weeks. This disappointment led to a 2.7% dip in its stock, while rival Cytokinetics may find new opportunities for its drug aficamten. Analysts emphasize the unique challenges posed by different forms of HCM.